Trump downgrades medical marijuana's federal drug classification
Summary
The Justice Department downgraded state-licensed medical marijuana to a Schedule III drug, a historic shift easing research barriers and reshaping cannabis operations. Senator Tom Cotton criticized the move, citing concerns about increased potency and public safety.
How coverage differs
Left outlets emphasize Trump's historic reclassification of medical marijuana as a major policy shift easing research, while right outlets report the change but also highlight public safety concerns.
- Left: Historic reclassification eases medical marijuana research, reshapes cannabis industry Left-leaning outlets emphasize President Trump's Justice Department's historic reclassification of state-licensed medical marijuana to a Schedule III drug. They highlight this significant shift as easing research barriers and potentially reshaping the cannabis industry, framing it as a major policy change.
- Right: Downgrading marijuana classification risks public safety, potency concerns Right-leaning outlets report President Trump's administration reclassified medical marijuana as a less dangerous Schedule III drug, noting its potential impact on the cannabis industry. They also highlight criticism from figures like Senator Tom Cotton, who expressed concerns about increased potency and public safety risks.